Synergistic Cardiac Protection by Thymoquinone and Valproic Acid in Absence Epilepsy

Area of Science:

• Cardiovascular Research
• Neuroscience
• Pharmacology

Background:

• Absence epilepsy (AE) can induce molecular changes in cardiomyocytes.
• Oxidative stress, apoptosis, and inflammation are implicated in cardiac damage.
• Investigating potential therapeutic agents for AE-related cardiac complications is crucial.

Purpose of the Study:

• To evaluate the protective effects of thymoquinone (T) and valproic acid (VPA), individually and in combination, against AE-induced cardiomyocyte damage in rats.
• To assess the impact of T and VPA on oxidative stress, apoptosis, and inflammation markers in cardiac tissue.

Main Methods:

• Adult male Wistar rats and Genetic Absence Epilepsy Rats from Strasbourg (GAERS) were used.
• Experimental groups included control, AE, AE+T, AE+V, and AE+V+T.
• Treatments (T: 10 mg/kg, VPA: 200 mg/kg) were administered for 8 days, followed by histological and biochemical analyses of heart tissue.

Main Results:

• AE significantly increased oxidative stress markers (TOS, OSI, MDA) and apoptosis markers (caspase-8, cleaved caspase-3), alongside elevated inflammatory cytokines (TNF-α, IL-6) and NF-κB.
• Both T and VPA demonstrated partial protective effects, improving antioxidant status and reducing some damage markers individually.
• The combination of VPA and T showed synergistic effects, significantly attenuating oxidative stress, apoptosis, and inflammation markers more effectively than either agent alone.

Conclusions:

• Absence epilepsy induces significant oxidative stress, apoptosis, and inflammation in cardiac tissue.
• Thymoquinone and valproic acid offer protective benefits against AE-induced cardiac damage.
• Combined administration of thymoquinone and valproic acid presents a promising therapeutic strategy for mitigating cardiac complications associated with absence epilepsy.